Locations:
Search
Guidance on patient selection, safety surveillance, choosing among agents and more
Phase 3 trial found no survival differences between weekly or biweekly doxorubicin/cyclophosphamide or between weekly or biweekly paclitaxel
Findings show no increased risk in long-term outcomes
Findings strengthen evidence for risk-reducing procedures
Combined expertise, collaboration and technology lead to several improvements
Less than 50% of patients with diabetes get appropriate ophthalmic screening through primary care referrals
Findings from large database important to inform clinical practice
Socioeconomic disparities have a notable influence on access to allogeneic hematopoietic cell transplant
Study identifies Ketorolac as a potential repurposable drug
Authors summarize the recent evidence and offer two clinical scenarios
Offers a new option for patients 60 and older with relapsed/refractory disease
Post hoc analysis of PROTECTED TAVR finds reduced stroke risk in the U.S. but not beyond
Rare genetic disorder prevents bone mineralization
New developments offer providers more sophisticated options
Conservative treatments were ineffective for 29-year-old with chronic heel pain
A review of current evidence and recommendations